A Bayesian Analysis of the Impact of Hereditary Attributes on the Diagnosis of ALS Patients by Coleman, Kathryn Dee
University of Memphis 
University of Memphis Digital Commons 
Electronic Theses and Dissertations 
12-4-2015 
A Bayesian Analysis of the Impact of Hereditary Attributes on the 
Diagnosis of ALS Patients 
Kathryn Dee Coleman 
Follow this and additional works at: https://digitalcommons.memphis.edu/etd 
Recommended Citation 
Coleman, Kathryn Dee, "A Bayesian Analysis of the Impact of Hereditary Attributes on the Diagnosis of 
ALS Patients" (2015). Electronic Theses and Dissertations. 1320. 
https://digitalcommons.memphis.edu/etd/1320 
This Thesis is brought to you for free and open access by University of Memphis Digital Commons. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of University of 
Memphis Digital Commons. For more information, please contact khggerty@memphis.edu. 
A BAYESIAN ANALYSIS OF THE IMPACT OF HEREDITARY ATTRIBUTES ON 
THE DIAGNOSIS OF ALS PATIENTS 
by 





Submitted in Partial Fulfillment of the 
Requirements for the Degree of  
Master of Science 
 




The University of Memphis 
December 2015  
ii 
Dedication 
 To Mrs. Liz Bias—a mother figure to most, a best friend to many, and a role 
model to me.  My prayer for the continuation of ALS research resonates from a wish 
within—a hope to minimize a deficit of ALS knowledge for the future in honor of a 
woman that did not deserve any deficits in her life.  Thank you for being my motivation 
for this analysis—you’ve done more for me than you will ever know.  ALS is no longer 
able to keep you from laughing that contagious laugh.  May you rest in peace knowing 
the fight against ALS and the race to find a cure will never cease. 
 Additionally, this research is dedicated to Dr. Dale Bowman’s father, James 
Bowman.  Our smartest statisticians shouldn’t have to speculate about the progression 










With the encouragement (and patience) of my advisor and editor Dr. Dale, as well 
as the support from my parents, family, friends, and fiancé Ross, the light at the end of 
my research tunnel is closer and within reach.  Thanks to all. 
This thesis was written to offer a different Bayesian approach on the research of 
the recognizably and often swift progression of ALS in diagnosed patients.  One day, 
families and patients themselves will not be as overwhelmed by the disease’s aspects as 
they are today.  Only continued research will determine how to ease those adjustments, 












 “Not only does God definitely play dice, but He sometimes confuses us by throwing them 




The purpose of this study is to determine the relationship between hereditary attributes of 
patients that have been diagnosed with ALS and the change in their respective ALSFRS 
and/or ALSFRS-R scores over the length of a clinical trial in which they participated.  
These scores assess the patient’s ability to perform everyday tasks, as well as describe the 
capability to breathe and eat.  Data for each of the 8,600 patients was collected by a 
group called PRO-ACT, and was de-identified prior to access.  Bayesian methods are 
used to estimate the mean of the posterior distributions of parameters in a simple linear 
model.  Gibbs sampling is used to estimate posterior distributions of regression 
parameters in order to determine which covariates may affect the progression of ALS as 
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Amyotrophic lateral sclerosis, more commonly “ALS”, is identified as a disease 
that debilitates a diagnosed patient by steadily deteriorating the brain’s motor neurons, 
according to a 2010 report by the National Institute of Neurological Disorders and Stroke 
(NINDS).  These neurons control voluntary muscle movement, and are found in the 
brain, its stem, and the body’s spinal cord (NINDS, 2010).  Once a motor neuron is dead, 
it can no longer send signals from the brain to the muscles throughout the body, most 
noticeably the legs, arms, and face after symptom onset.  Eventually, enough motor 
neurons die, causing more muscles to weaken, thus limiting mobility and normal bodily 
functions.  This, in turn, limits respiratory ability, which is the most common cause of 
death among ALS patients (NINDS, 2010).  ALS-caused respiratory failure victims tend 
to pass away within three to five years, according to the National Institute of 
Neurological Disorders and Stroke (2010), but roughly ten percent of diagnosed patients 
live ten or more years after symptoms begin.  Although muscular degeneration occurs, 
the five senses of the human body are seemingly unbothered (NINDS, 2010).  Even 
though a patient may experience depression, the functions of the mind, emotions, and 
intellect remain virtually unaffected. 
  When this research first launched, I alleged that there would not be enough 
chronological research on ALS, and definitely not enough history of the disease.  I 
presupposed that there would be too many unanswered questions still remaining that 
would hinder my ability to work toward a personal contribution to research in this area.   
I assumed that if we, as a community, were not learning about new ALS treatment 
advances as often as cancer cure breakthroughs, then it must follow that extensive 
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research and detailed histories must not exist either.  I was only slightly mistaken—the 
research is happening, but the underlying questions are not being resolved. 
Many researchers have conducted genetic analyses on the DNA of ALS patients, 
using a scientific approach based solely on whether or not a patient’s family member had 
been previously diagnosed.  There are numerous statistics that are generally known when 
it comes to ALS.  According to NINDS (2010), one of these includes “ALS is more 
common among white males, non-Hispanics, and persons aged 60-69 years” (p. 2).  
Unfortunately for both researchers and patients, NINDS also reports that “in 90 to 95 
percent of all ALS cases, the disease occurs apparently at random” (p. 2).  Should this 
“randomness” not be a concern of the general public?  Are we not diagnosing ourselves 
with a surprise disease by taking the back seat when it comes to research?  Uncertainty 
abounds. 
Many people have heard of “Lou Gehrig’s disease” and its namesake’s famous 
slugger of an athlete.  Most have acknowledged the name “Stephen Hawking” as the 
most brilliant scientist since Einstein, having literally written the book on our universe’s 
black holes (Biography.com, Hawking).  Still, the fundamental paradox between these 
two men continues to beg for an answer.  Why did Lou Gehrig not live as long as 
Stephen Hawking after onset of symptoms and diagnosis?  Both are males, diagnosed in 
early age, but Hawking is now 73 years old, while Gehrig passed away at age 38 
(Biography.com, Gehrig).  Was it a hereditary trait that allowed Hawking to prolong his 
life?  Did Gehrig’s disease overcome him more quickly because his parents were German 
(Biography.com, Gehrig)?  The probing questions linger. 
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Upon mentioning the term “ALS” in conversation, most everyone knows at least 
one person in his or her community that has been diagnosed.  In my childhood, my 
mother had a church choir friend that would watch us after school.  Having known this 
woman for so long, it was difficult to decipher why, now all of a sudden, she was tripping 
on her own feet.  She had also begun taking notice that her hands weren’t working like 
they had before.  The diagnosis was ALS, and within the year she had lost her ability to 
walk, as well as the capacity to complete a plethora of daily tasks.  Within two years of 
her foretelling fall in the choir loft, ALS had taken her life.  Why did ALS progress so 
quickly in her?  Her family, like many others, yearns to find answers. 
The intention of this paper and accompanying research analysis is not to 
necessarily answer these vexing questions posed.  Instead, it is to offer another approach, 
an additional line of attack, in an attempt to further the development of ALS prognoses 
and predictions. 
Area of Focus 
 The purpose of this research is to introduce a simplified analysis of ALS data 
using the methods of Bayesian modeling.  Intentions for an end result are to predict the 
likelihood of survival and length of life after the diagnosis of ALS using distinct patient 
characteristics such as family history, demographics, and ALSFRS(-R) data.  Bayesian 
methods allow analysts to consider both prior and posterior distributions.  Posterior 
distributions of the parameters of a linear model relating hereditary data, family history of 
the disease, and patient demographics to ALSFRS(-R) scores, a measure of the 
progression of the disease, will be derived. These posteriors will be useful to determine 
what factors affect the progression of ALS as measured by their ALSFRS(-R) scores. 
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Review of Related Literature and Research 
Since the cataloging of ALS began, multiple studies have been conducted in order 
to predict various factors that “cause” ALS.  Researchers, like patients, tend to want to 
know the basics: who, when, and why.  Making inferences on these basics will assist in 
the further analysis of the complexities of the disease, such as survival time and effective 
treatment options that may vary from patient to patient. 
The Who 
Scientists wish to determine who will be diagnosed with the disease in the future 
by studying the genetic and hereditary attributes of patients that are already diagnosed.  
Various analyses have been conducted in order to find mutations in genes, enzymes, and 
other patient diagnosis identifiers.  In the United States today, there are approximately 
30,000 people diagnosed with ALS, which amounts to the death of two people for every 
100,000 deaths annually (ALSA.org, 2015). 
To this date, there has been no definite flag of the disease for sporadic cases, such 
as an enzyme in the blood or lesion on the skin like other diseases.  However, there have 
been many distinctive genetic characteristics of ALS, especially those of familial ALS, 
also termed FALS (Gros-Louis, Gaspar, & Rouleau, 2006).  In 2006, an article was 
published in the journal ScienceDirect and stated that at that time, eight FALS loci and 
six ALS-related genes had been discovered (Gros-Louis et al., 2006).  Loci, plural of 
locus, are locations on a certain chromosome for a particular gene (Loci, 2015).  Familial 
ALS accounts for 5-10% of all ALS diagnoses (Kortebein & Means, 2013), and the only 
“classifier” of further FALS classification rather than regular ALS is that a family 
member was diagnosed as well.  These discoveries seemed to have only led to additional 
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patterns and more questions.  The ALS-related genes are not necessarily spot-on 
identifiers or predictors of the disease, but rather mutations in them.  Accounting for 
approximately 15% of the small population of inherited FALS, a mutation in the gene 
called SOD1 (Cu/Zn superoxide dismutase) has been a prevalent characteristic between 
patients (Gros-Louis et al., 2006).  If a parent has been identified as having the mutation 
of SOD1 in their genetic makeup, every offspring of that parent is 50% likely to carry the 
gene, which is later attributed to the diagnosis and development of ALS (Mitsumoto, 
2009).  Gros-Louis et al.’s article on FALS states (2006), 
Despite intensive research efforts, the mapping and the identification of genes 
responsible for classical form of FALS has met with limited success.  This 
difficulty arises in part because large families with sufficient statistical power for 
linkage analysis are hard to come by due to the late onset and age-dependant 
penetrance of the disease, and the relative short survival time of affected ALS 
patients. (p. 956) 
The When 
Naturally, recently diagnosed patients of any disease may have the inclination to 
ask, “When will I die?”  or, “How much time do I have?”  While this is a tough question 
to answer, we revert back to the fact that physicians are usually able to confidently 
answer this question when it arises with other diseases.  For example, doctors are almost 
always capable of predicting a cancer patient’s life expectancy after diagnosis.  This 
prediction, however, hasn’t commonly become accurately available to ALS patients.   
In Hiroshi Mitsumoto’s patient and family guide to ALS, contributing author 
Valerie Cwik (2009) makes the following statement: 
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Although researchers are looking for bio-markers (blood tests, imaging studies, 
and other tests) that will allow for more precise and earlier diagnosis, at the 
present time there is no single laboratory test that allows one to make a diagnosis 
of ALS with 100% certainty, particularly in its early stages. (p. 27) 
As researchers, we look for patterns, signs, and indicators that lead to a breakthrough in 
the development of a disease when studying its life cycle and prognosis.  Have we failed 
or not kept ahead of the curve in the instance of ALS?  Have we not been able to provide 
physicians with adequate information to accurately diagnose a life-threatening disease 
early enough?  If doctors are unable to classify a person’s clumsy feet and slowing hand 
skills as ALS in the early stages, how will we ever get to the point of productive therapy 
and possible cure for this rapidly progressive disease? 
 Furthermore, the forecast for a diagnosed patient seems too vague.  Patients hold 
on to hope that their type of ALS is the same as Stephen Hawking’s in that they are still 
able to live a long life.  This is especially the case when physicians are still in the 
elementary stages of understanding and diagnosing the disease.  The median length of the 
disease—from diagnosis until death—ranges from 23 to 52 months (Mitsumoto, 2009).  
According to Mitsumoto, in one of the latest studies in 2009, it was concluded that if the 
patient maintains a certain mental health, that the patient’s prognosis is extended. 
The Why 
Researchers would like to know more about the disease itself in general.  Since 
specific genes have been identified as being related to ALS, the possibility exists that 
there are more unidentified ALS-connected genes.  Since its first discovery of familial 
mutation over 22 years ago, SOD1 has been the only genetic link to almost 20% of the 
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FALS cases, which is only approximately 10% of the ALS-diagnosed population (Gros-
Louis et al., 2006).  This, in turn, leads researchers to believe that another gene or 
mutation must exist that are definite characteristics of FALS, and possibly ALS. 
Data Collection and Sources 
 Although ALS is still considered a rarely diagnosed disease, there have been a 
large number of records obtained from over 8,600 patients that participated in various 
clinical trials.  The PRO-ACT (Pooled Resource Open-access ALS Clinical Trials) 
database contains case-specific information from various trials on the progression and 
treatment of ALS.  To date, it is the largest compilation of de-identified patient data 
according to the Neurological Clinical Research Institute, or NCRI (2015). 
In order to protect privacy of ALS patients within its database, all personal 
identifiers were removed, and “SubjectID” numbers were assigned.  For each observation 
or clinic visit, an alpha-numeric record locator was assigned randomly (NCRI, 2015).  
The data were collected from varying trials, and their unique trial identifiers were also 
discarded. 
 Data from all the experimental tests were compiled and then separated into PRO-
ACT’s individual assessment files.  In total, there exist 11 type files.  In order to focus on 
the research questions posed, the five files and their descriptions used in this analysis are 
as follows: 
 ALSFRS(-R):  The ALS Functional Rating Scale (ALSFRS) and its revised 
version ALSFRS-R are scores that assess the symptom severity during each clinic 
visit for each patient.  The score data are separated into 10 symptom assessments, 
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with ratings ranging from 0 (complete loss of function) to 4 (normal function) for 





5. Cutting food and handling utensils (with or without gastrostomy) 
6. Dressing and hygiene 
7. Turning in bed and adjusting bed clothes 
8. Walking 
9. Climbing stairs 
10. Breathing 
Some ALS patients are diagnosed with dysphagia, which causes problems in 
processing food and sustaining nutritional nourishment, and can sometimes lead to 
decrease in weight as well as breathing difficulties while eating (“Gastrostomy in 
patients,” 2015).  When this occurs, the physician may elect to carry out a gastrostomy 
procedure.  This is a way to provide lasting dietary sustenance to the patient without 
choking or prolonged feeding times due to dysphagia. 
With ALSFRS-R, the score for the “Breathing” assessment was broken down into 
three additional responses in order to more accurately assess respiratory function.  Those 
three responses include respiratory difficulties including dyspnea, orthopnea, and 
respiratory insufficiency (NCRI, 2015).  
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 Death Report:  This data simply displays one statistic—whether death occurred 
during the clinical trial.  If so, the file also lists the number of days (also called the 
delta) since the patient began the trial. 
 Demographics:  This assessment file’s data is collected in the beginning of the 
trial and includes patient physical characteristics such as age, gender, race, and 
age at onset (NCRI, 2015). 
 Family History:  As mentioned previously, about 5% of ALS cases are considered 
familial, or hereditary.  This file outlines which family member of the diagnosed 
patient was also diagnosed with ALS. 
 Subject ALS History:  The history of the progression of ALS within a patient is 
vital to determining what is next in the duration of the disease.  As ALS begins to 
take over the body, the patient will experience the loss of different parts of the 
body at varying times.  This file contains data that identifies the site of onset, as 
well as the different sites of muscle loss as the disease wears on. 
In each file, there is a delta listed for each assessment by patient record.  The number 
defined to be the delta for each visit/assessment is equivalent to the number of days since 
the patient began the respective trial; negative values for delta indicate that the trait being 
assessed occurred previous to trial start. 
Interestingly enough, the PRO-ACT organization has also recognized that ALS is 
only diagnosed given its symptoms, and that there is no unique test that will show that a 
patient is unquestionably suffering from ALS.  According to PRO-ACT data and NCRI 
(2015), “the gap in time between onset of symptoms and diagnosis is on average more 
than a year.”   A person may be led to believe that by the time a year or more passes, that 
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ALS would continue to progress without treatment.  This could cause a quicker 
progression of the disease, or even worse, death before diagnosis. 
Organizing the Data 
 After acquiring the 26 datasets from the PRO-ACT database, manually coded 
links had to be made from each downloaded zipped file in order to compile data for each 
patient.  The 13 zipped folders in the list pictured Figure 4 in the “Figures” section of the 
Appendix each contained two files:  a “Data” file containing the observational recorded 
data by patient and Record ID, as well as a “Data Dictionary” which was a general 
explanation of the coding that was used in compiling the data during the clinical trials 
(see Table 3 in the Appendix for Data Dictionary codes).  To get an idea of what the 
messy original files looked like directly after download, see Figures 5 and 6 in the 
Appendix.  Since downloaded datasets were not previously separated into fields specified 
by their headers, the “Text to Column” feature in Microsoft Excel was implemented and 
columns were separated (see Appendix, Figures 7 and 8).  Then, in the Data Files, 
reference formulas were written to lookup each respective Data Dictionary code to create 
a fuller picture for each patient. 
Unnecessary data was removed from further consideration, as we were interested 
in the ALSFRS and ALSFRS-R scores, patient demographics, family history, patient 
history, and death data.  For this analysis we are interested in only the patients with 
complete records.  Although only 20.6% of all the compiled patients had what we 
considered “complete” records, it still left us with 1,753 patient records that contained 
information regarding gender, age, race, location onset, onset delta days, death of the 
patient, and either a corresponding ALSFRS or ALSFRS-R score. 
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Variable Selection and Methods Used 
 Given the PRO-ACT datasets, the goal is to predict the expected prognosis of an 
ALS patient after diagnosis.  In the PRO-ACT files, we have ALSFRS and ALSFRS-R 
scores (further referred to as ALSFRS(-R) scores) which measure the advancement of the 
disease for each patient.  The scores are assessed at each clinic visit over the period of the 
clinical trial, and correspond to respective delta values.  The deltas are measured in days 
since the trial began.  These scores will represent our response variable.  In a Bayesian 
analysis performed by Gilks, Richardson, and Spigelhalter (1998) on Gambian infants 
infected with Hepatitis B (HB) called the “Gambian Hepatitis Intervention Study” 
(GHIS), two blood samples were taken from each observed infant over a length of time 
after vaccination was administered.  Our data for the observed ALS patients is similar in 
that over the period of a clinical trial, ALSFRS(-R) scores are assigned by assessors 
(assumed clinicians, nurses, or physicians).  Thus, we will model our analysis similar to 
the GHIS analysis. 
First, we wish to develop a simple linear model which describes the change in the 
ALSFRS(-R) score over time.  We will be interested in the ALSFRS(-R) score assigned 
at the initial visit, the final visit, and the difference of the two.  We will assume that each 
clinical trial lasted an equal number of days.  However, we cannot assume that each 
patient’s final assessment was on the last day of the trial.  Thus, the delta in days from 
initial to final score may differ for each patient.  We will also assume that if the final 
score is equivalent to zero, that the patient passed away before the end of the trial. 
The data provided include score records, demographics, patient history, family 
history, and death data.  PRO-ACT data was collected worldwide, varying in notation 
12 
 
from trial to trial, so portions of the datasets are rather messy.  The datasets contain 
observations from over 8,600 patients, but some observations or patients as a whole were 
omitted due to lack of score data. 
Let     represent the ALSFRS(-R) score given to patient i at the initial clinic visit, 
where t = 0.  This will be considered a baseline score, and we are interested in the change 
from this initial score to the final score assigned to patient i over their respective number 
of delta days from initial visit until final assessment,   .  The change in the score over 
time    will be defined as            , where    represents the final visit for patient i.  
The differences in scores may be distributed as          
    where   is unknown. 
Let    represent the maximum delta for each patient, since the corresponding 
ALSFRS(-R) score is assumed to be the final score, and is subtracted from the initial 
score.  Every patient’s    value differs since scores were assessed at various times, and 
some patients expired before the trial ended.  Since we are considering the impact of 
covariates, we will assign identifier variables,    , to represent patient attributes: 
     
        
           
  
                     
     
                 
           
  
     
               
           
  
     
                       
           
  
Let 
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for         where         is the total number of observed patients in our sample, 
and where    are regression coefficients distributed as  
            
    
The priors on    are non-informative priors that are normally distributed with mean zero 
and large variance, since we are unaware of any previous information that their respective 
parameter    or attribute     may contain. 
Before beginning the analysis, we look at the data using exploratory methods.  By 
plotting the raw data for difference in final and initial scores versus the number of days 
passed when the final score was assessed, we are able to see in Figure 1 that the longer a 
patient is observed, the larger the difference becomes between a patient’s initial score and 
their final observed ALSFRS(-R) score, which is expected.  This is analogous to stating 
that a patient’s score will decline incrementally if given more days to be measured.  
Figure 1 simply shows the relationship between delta days and score decrease for each 
patient.  It does not serve as our predictor model since it does not take into consideration 
our covariates.  We may also use a function in R software called “predict()” in order to 
investigate the predicted score change in a patient given certain attributes for this raw 
data linear model.  Based solely on the linear model in R defined as  
lm (Y ~ time + sex + age + bulbar onset + limb onset + death), (LM.1) 
we can create confidence intervals for predicting the decrease in score for each patient.  
For example, we have a 55-year-old female diagnosed with ALS and having had limb 
onset symptoms, and death at 730 days.  We are able to predict that her decrease in score 
would have been 22.525 points at 97.5% confidence.  This, however, does not seem to be 
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a true fit.  We would expect a larger decrease in points since given the information that 
death occurred. 
 
 Figure 1:  Delta Days versus Difference in ALSFRS Score 
 
 
We will assume all individual    differences in scores are independent of each 
other between patients, conditional on their respective means,   , as well as an unknown 
  parameter, which directs the sampling error (Gilks, Richardson, & Spiegelhalter, 1998).   
 A directed acyclic graph, or DAG (see Figure 2) is illustrative of the “parent 
nodes” of each parameter.  Thus, a DAG allows us to assume that “the joint distribution 
of all the random quantities is fully specified in terms of the conditional distribution of 
each node given its parents” (Gilks et al., 1998).  It also gives us a better picture of the 




Figure 2:  DAG illustrating our model’s nodes and priors on parameter nodes.  
 
 
For the set of priors without parent nodes,     and    
 , we will assume they are 
normally distributed with mean equivalent to zero and large variance.  Using similar 
priors as Gilks et al. (1998) and the study on GHIS infants, we let the variance be 
distributed as large as possible, and since we are programming in BUGS (and later in R), 
we use the precision tau ( ) instead of the variance where       .  Since we want the 
variance to be large, we let                     . 
Now, we are interested in the mean,   , of the posterior distribution.  We will use 
Gibbs sampling to fit our model, and implement the sampling via statistical software 
referred to as BUGS.  Known for its ability to easily work with Bayesian modeling, our 
programming choice was BUGS, which is an acronym for “Bayesian Inference Using 
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Gibbs Sampling” (Lunn, Jackson, Best, Thomas, & Spiegelhalter, 2013).  We will also 
implement R programming software in order to further verify our model. 
To set up our process, we first provide initial values for all priors on parameter 
nodes that we want to observe.  We want the Gibbs sampler to overlook its starting 
values since they are unimportant.  We will perform cycles, or runs, with initial values 
shown in Table 2 in the Appendix.  We also implement one chain for each run since we 
have separated our initial values into three separate vectors.  In our first run, we choose 
starting values based on the least squares estimate of each parameter.  In our second and 
third runs, we set our initial values to be considerably different than those in the first run.  
We hope that our sampler will eventually “forget” its initial states and begin to converge 
to one estimated value. 
According to Gilks et al. (1998), Gibbs sampling iteratively draws samples from 
the “full conditional distributions of unobserved nodes in the graph” ( p.29).  After 
preparing our beginning values for each run, we may construct a fully conditional 
distribution for each node in the DAG.  Thus, referring back to for any node, say x, in our 
Bayesian model, we can represent the other nodes (not node x) as     and rewrite our 
model as the proportion 
                    
where 
                                                                (P.1) 
As demonstrated in (P.1), the fully conditional distribution for x has a prior probability 
               .   
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In monitoring the output, the values generated by the Gibbs sampler must be 
checked for convergence and intermingling, and can be done so visually in a graph called 
a trace plot, as well as checked through the statistical output (Gilks et al., p.31).  We will 
run 5,000 iterations and 500 “burn-ins” for each run separately using our starting values 
in Table 2 in the Appendix.  We will also limit our sample to the first 1,000 patient 
records in our dataset in order to quickly receive an output.  Using the full set 1,753 
patients at 5,000 iterations slows the software, and will eventually shut down the 
software, giving a runtime error.  From Run 1, Run 2, and Run 3, we display the trace 
graphs as well as the densities for each parameter in Figures 9a, 9b, and 9c, respectively.  
We are able to see that each of the three runs is converging to the same posterior 
distribution (see Output, Appendix).  We also have posterior means for each    in each 
run.   
With our output, we can investigate point estimates of the mean of each 
parameter, as well as the highest posterior density (HPD) intervals.  These intervals are 
created using our simulated data, so in turn consider the fact that the data the interval is 
based on is simulated (Ghosh, Delampady, & Samanta, 2006).  These intervals also work 
well when the distribution is bimodal (Ghosh et al., 2006).  In Table 1, we list the 
estimates and 97.5% HPD intervals for Run 1.  The other two runs gave very similar 
values, so we will investigate the first.  From Table 1, it appears that the variables of time 
(delta days) and death,    and    respectively, impact our response the most.  Thus, we 
are able to conclude that these greatly impact the mean of   , and are significant in 








As with most statistical modeling, we are not only interested in the sample we 
have obtained, but also what the sample may represent about the population from which 
it was drawn.  This will allow us to extrapolate results for future patients.  We have 
developed a model using Bayesian methods with non-informative priors on the 
parameters.  Now, we are able to better predict the decrease in score given delta days, 
patient attributes, and death data.  
In Figure 3, our models have been plotted using R software.  The black line and 
gray points are representative of our sample data and simple regression model (LM.1) 
from page 13.  For our three runs, we have plotted the simulated data given the 
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Figure 3:  Linear regression models:  Black = lm(Y ~ time + sex + age + bulbar + limb + 




After analyzing our data and outputs, we developed a Bayesian model for the 
change in ALSFRS(-R) scores using non-informative priors.  We have applied Gibbs 
sampling in order to compute the posterior distributions of the parameters of our linear 
model and in the process, obtained point estimates of those parameters.  We were also 
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able to conclude from our model that an ALS-diagnosed patient with a longer survival 
time tends to have a larger difference between the initial and final ALSFRS(-R) scores 
than those patients with shorter survival times. 
Interpretation and Recommendations 
 From this study, many things have been learned, both from a statistical point of 
view and a research point of view.  From the data standpoint, we have learned that even if 
we are provided a large dataset with multiple variables and factors, it does not imply that 
all aspects need to be used in formulating a statistical model, and many observations 
(patients) may be excluded if complete records are required.  In beginning this research, 
we had hoped to use as many variables as possible to describe the patients, even 
considering multiple multivariate regression.  However, as data organization became a 
hindrance, we decided to limit the number of covariates to gender, age, onset 
symptom(s), days since onset, and whether or not the patient died during the clinical trial. 
 From a research standpoint, it was very interesting to learn about the small 
percentage of familial ALS and how genetic data has already been identified.  As for the 
sporadic cases of ALS, the vast emptiness of research developments was astounding.  
However, this deficit simply signifies an opportunity for future researchers on the 
prognosis of ALS. 
 As a recommendation for continuation of this study, a more sophisticated 
approach that includes the patient records that do not contain all the covariates may be 
developed.  Due to the various clinical trials and their respective directors, unfortunately 
not all data was collected uniformly.  Further, additional covariates that are available in 
the Data Files may be considered, including clinical data regarding the administering of a 
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placebo drug versus the clinical drug being tested, as well as lab results.  It is also 
possible that the ALSFRS(-R) scores may not be a good predictor of disease progression. 
 Although tobacco use data, drug use data (including prescription and non-
prescription drugs), and alcohol use data are not collected in the PRO-ACT Data Files, it 
would be interesting to see the effects of these covariates on a patient’s ALS prognosis.  
Another factor that would be interesting to consider would be patient environmental 
factors.  Examples might include the city’s air quality index in which the patient resides, 
or the quality of drinking water in the area.  Also, genomic information could be of 
particular use if it were collected. 
In an article published in 2010, Anthony Hardie recaps a presentation made by 
researcher Dr. Ronnie Horner from the University of Cincinnati discussing the prevalence 
of ALS diagnoses among Gulf War veterans that served in 1991, deployed and non-
deployed service members.  Dr. Horner goes on to examine the fact that over half of the 
ALS-diagnosed veterans were 25-years-old or younger, and 98% younger than 55-years-
old (Hardie, 2010), which is the average age of diagnosis.  While searching for a common 
theme among these diagnoses, Dr. Horner considers environmental factors such as 
exposure to heavy metallic substances in the land where they served, substances in the 
vaccine for anthrax, as well as significant damage to the head during training or in battle.  
His hypothesis states that these men and women were exposed to chemical agents during 
the Khamisiya demolition in 1991, and that this exposure triggered an elevated risk to 
developing ALS (Hardie, 2010). 
 This project was begun in hopes of submitting the analysis and results to a 
national research competition called the “DREAM ALS Stratification Prize4Life 
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Challenge” (Prize4Life, 2015).  This contest asks the contestants to predict either the 
progression of ALS using the ALSFRS(-R) scores, or to predict the probability of 
survival within a given time period post-diagnosis.  We plan to continue this work into 
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Table 1:  Posterior means, standard deviation, and confidence intervals for each   . 
 
Table 2:  Gibbs sampler beginning values (inits) for parameters 
Parameter Run #1 Run #2 Run #3 
b0mu 3 60 0 
b1mu 0.019 20 0 
b2mu -0.264 -20 0 
b3mu -0.024 -20 0 
b4mu 1.256 30 0 
b5mu -0.803 -20 0 
b6mu 7.048 90 0 
b0tau 0.001 0.00001 10 
b1tau 0.001 0.00001 10 
b3tau 0.001 0.00001 10 
b4tau 0.001 0.00001 10 
b5tau 0.001 0.00001 10 
b6tau 0.001 0.00001 10 




Table 3:  Compiled list of Data Dictionaries and coding of areas of interest in Data 
Files—Demographics, ALSFRS and ALSFRS-R Scores, Family History, Patient History, 











FormID FormName Form_CDISC_Name FieldID Field_Name Field_CDISC_Name Field_Description Value
144 Demographics NULL 1203 Demographics Delta DEMDLTA NULL NULL
144 Demographics NULL 1204 Ethnicity ETHNIC NULL Hispanic or Latino
144 Demographics NULL 1204 Ethnicity ETHNIC NULL Non-Hispanic or Latino
144 Demographics NULL 1204 Ethnicity ETHNIC NULL Unknown
144 Demographics NULL 1205 Sex Sex NULL Female
144 Demographics NULL 1205 Sex Sex NULL Male
144 Demographics NULL 1206 Race - American Indian/Alaska Native RCEAMIND NULL NULL
144 Demographics NULL 1207 Race - Asian RCEASIAN NULL NULL
144 Demographics NULL 1208 Race - Black/African American RCEBLACK NULL NULL
144 Demographics NULL 1209 Race - Hawaiian/Pacific Islander RCEHAW NULL NULL
144 Demographics NULL 1210 Race - Unknown RCEUNK NULL NULL
144 Demographics NULL 1211 Race - Caucasian RCEWHITE NULL NULL
144 Demographics NULL 1257 Age Age NULL NULL
144 Demographics NULL 1393 Race - Other RCEOTH NULL NULL
144 Demographics NULL 1394 Race Other Specify RCEOTHSP NULL NULL
145 ALSFRS(R) NULL 1213 1. Speech ALSFRS1 NULL NULL
145 ALSFRS(R) NULL 1214 10. Respiratory ALSFRS10 NULL NULL
145 ALSFRS(R) NULL 1215 2. Salivation ALSFRS2 NULL NULL
145 ALSFRS(R) NULL 1216 3. Swallowing ALSFRS3 NULL NULL
145 ALSFRS(R) NULL 1217 4. Handwriting ALSFRS4 NULL NULL
145 ALSFRS(R) NULL 1218 5a. Cutting without Gastrostomy ALSFRS5A NULL NULL
145 ALSFRS(R) NULL 1219 5b. Cutting with Gastrostomy ALSFRS5B NULL NULL
145 ALSFRS(R) NULL 1220 6. Dressing and Hygiene ALSFRS6 NULL NULL
145 ALSFRS(R) NULL 1221 7. Turning in Bed ALSFRS7 NULL NULL
145 ALSFRS(R) NULL 1222 8. Walking ALSFRS8 NULL NULL
145 ALSFRS(R) NULL 1223 9. Climbing Stairs ALSFRS9 NULL NULL
145 ALSFRS(R) NULL 1225 ALSFRS Delta ALSFDLT NULL NULL
145 ALSFRS(R) NULL 1228 ALSFRS Total ALSFRST NULL NULL
145 ALSFRS(R) NULL 1229 ALSFRS-R Total ALSFRSRT NULL NULL
145 ALSFRS(R) NULL 1230 R-1. Dyspnea ALSFRSR1 NULL NULL
145 ALSFRS(R) NULL 1231 R-2. Orthopnea ALSFRSR2 NULL NULL
145 ALSFRS(R) NULL 1232 R-3. Respiratory Insufficiency ALSFRSR3 NULL NULL
147 Family History NULL 1236 Family History Delta FAMHXDLT NULL NULL
147 Family History NULL 1287 Family History of Neurological Disease NULL NULL ALS
147 Family History NULL 1287 Family History of Neurological Disease NULL NULL DAT (Dementia Alzheimer's Type)
147 Family History NULL 1287 Family History of Neurological Disease NULL NULL Other
147 Family History NULL 1287 Family History of Neurological Disease NULL NULL Parkinson's Disease
147 Family History NULL 1288 Aunt Aunt NULL NULL
147 Family History NULL 1289 Aunt (Maternal) AUNTMAT NULL NULL
147 Family History NULL 1290 Aunt (Paternal) AUNTPAT NULL NULL
147 Family History NULL 1291 Cousin COUS NULL NULL
147 Family History NULL 1292 Cousin (Paternal) COUSPAT NULL NULL
147 Family History NULL 1293 Cousin (Maternal) COUSMAT NULL NULL
147 Family History NULL 1294 Father FATHER NULL NULL
147 Family History NULL 1295 Grandfather GFATH NULL NULL
147 Family History NULL 1296 Grandfather (Maternal) GFATHMAT NULL NULL
147 Family History NULL 1297 Grandfather (Paternal) GFATHPAT NULL NULL
147 Family History NULL 1298 Grandmother GMOTH NULL NULL
147 Family History NULL 1299 Grandmother (Maternal) GMOTHMAT NULL NULL
147 Family History NULL 1300 Grandmother (Paternal) GMOTHPAT NULL NULL
147 Family History NULL 1301 Mother MOTHER NULL NULL
147 Family History NULL 1302 Nephew NEPH NULL NULL
147 Family History NULL 1305 Niece NIECE NULL NULL
147 Family History NULL 1309 Sibling SIBLING NULL NULL
147 Family History NULL 1311 Uncle UNCLE NULL NULL
147 Family History NULL 1312 Uncle (Maternal) UNCLEMAT NULL NULL
147 Family History NULL 1313 Uncle (Paternal) UNCLEPAT NULL NULL
147 Family History NULL 1419 Neurological Disease NeurDis NULL NULL
147 Family History NULL 1420 Neurological Disease Other Specify NeurDSp NULL NULL
147 Family History NULL 1424 Son SON NULL NULL
147 Family History NULL 1425 Daughter DAUGHTER NULL NULL
147 Family History NULL 1426 Sister SISTER NULL NULL
147 Family History NULL 1427 Brother BROTHER NULL NULL
148 Subject ALS History NULL 1193 Site of Onset - Bulbar ALSONBLB NULL NULL
148 Subject ALS History NULL 1194 Site of Onset - Limb ALSONLM NULL NULL
148 Subject ALS History NULL 1200 Subject ALS History Delta ALSHXDLT NULL NULL
148 Subject ALS History NULL 1247 Symptom ALSSYMP NULL NULL
148 Subject ALS History NULL 1248 Symptom - Other (Specify) ALSSOSP NULL NULL
148 Subject ALS History NULL 1249 Location SYMPLOC NULL NULL
148 Subject ALS History NULL 1416 Site of Onset STONSET NULL Onset: Bulbar
148 Subject ALS History NULL 1416 Site of Onset STONSET NULL Onset: Limb
148 Subject ALS History NULL 1416 Site of Onset STONSET NULL Onset: Limb and Bulbar
148 Subject ALS History NULL 1416 Site of Onset STONSET NULL Onset: Other
148 Subject ALS History NULL 1416 Site of Onset STONSET NULL Onset: Spine
148 Subject ALS History NULL 1417 Onset Delta ONSTDLT NULL NULL
148 Subject ALS History NULL 1418 Diagnosis Delta DIAGDLT NULL NULL
219 Death Report NULL 1465 Subject Died SUBDIE Subject Died No
219 Death Report NULL 1465 Subject Died SUBDIE Subject Died Yes
219 Death Report NULL 1466 Death Days NULL Days after screening NULL
28 
 
Table 4:  Regression:  Delta Days vs. Initial Minus Final ALSFRS(-R) Scores.  From this 
table, we can see that our expected value of the set of intercepts is approximately 6.755, 
and the expected value of the set of slopes is 0.02076.  The plot of this data is displayed 


























df SS MS F Significance F
Regression 1 12581.4908 12581.4908 131.4423884 2.15361E-29
Residual 1751 167603.3938 95.71867151
Total 1752 180184.8846
Coefficients Standard Error t Stat P-value Lower 95% Upper 95% Lower 95.0% Upper 95.0%
Intercept 6.755260155 0.494238165 13.66802614 1.74179E-40 5.785901123 7.724619187 5.785901123 7.724619187






Figure 1:  Change in ALSFRS(-R) Score:  Initial Score minus Final Score.  This plot 
validates the assumption that as the days continue (Delta), the difference in the initial and 









Figure 3:  Linear regression models:  Black = lm(Y~time + sex + age + bulbar + limb + 


























Figure 3b:  Zoom-in on right side of regression models from Figure 3. 
 
 


























Figure 7:  Modified version of Demographics Data Dictionary after implementing “Text 





Figure 8:  Modified version of Demographics Data File after implementing “Text to 











Figure 9a continued:  Trace graphs of our parameters for Run 1. 
 
 
















































model{for (i in 1:N) { 
 Y[i] ~ dnorm(mu[i], tau) 
  x2[i] <- equals(sex[i],1) 
  x4[i] <- equals(bo[i],1) 
  x5[i] <- equals(lo[i],1) 
  x6[i] <- equals(death[i],1) 
 
mu[i] <- b0 + b1*t[i] + b2*x2[i] + b3*age[i] + b4*x4[i] + b5*x5[i] + b6*x6[i] 
} 
 b0 ~ dnorm(b0mu, b0tau) 
 b1 ~ dnorm(b1mu, b1tau) 
 b2 ~ dnorm(b2mu, b2tau) 
 b3 ~ dnorm(b3mu, b3tau) 
 b4 ~ dnorm(b4mu, b4tau) 
 b5 ~ dnorm(b5mu, b5tau)   
 b6 ~ dnorm(b6mu, b6tau) 
b0mu ~ dnorm(0, 10000) 
  b1mu ~ dnorm(0, 10000) 
  b2mu ~ dnorm(0, 10000) 
  b3mu ~ dnorm(0, 10000) 
  b4mu ~ dnorm(0, 10000) 
  b5mu ~ dnorm(0, 10000) 
  b6mu ~ dnorm(0, 10000) 
b0tau ~ dgamma(0.001, 0.001) 
   b1tau ~ dgamma(0.001, 0.001) 
   b2tau ~ dgamma(0.001, 0.001) 
   b3tau ~ dgamma(0.001, 0.001) 
   b4tau ~ dgamma(0.001, 0.001) 
   b5tau ~ dgamma(0.001, 0.001) 
   b6tau ~ dgamma(0.001, 0.001) 
tau ~ dgamma(0.001, 0.001) 
 sig2 <- 1/sqrt(tau) 
   b0sig2 <- 1/sqrt(b0tau) 
   b1sig2 <- 1/sqrt(b1tau) 
   b2sig2 <- 1/sqrt(b2tau) 
   b3sig2 <- 1/sqrt(b3tau) 
   b4sig2 <- 1/sqrt(b4tau) 
   b5sig2 <- 1/sqrt(b5tau) 
   b6sig2 <- 1/sqrt(b6tau) 
} 
list(N = 1753) 
 
#load inits 




 b0mu=3, b0tau=0.001, 
 b1mu=0.019, b1tau=0.001, 
 b2mu=-0.264, b2tau=0.001, 
 b3mu=-0.024, b3tau=0.001, 
 b4mu=1.256, b4tau=0.001, 
 b5mu=-0.803, b5tau=0.001, 






 b0mu=60, b0tau=0.00001, 
 b1mu=20, b1tau=0.00001, 
 b2mu=-20, b2tau=0.00001, 
 b3mu=-20, b3tau=0.00001, 
 b4mu=30, b4tau=0.00001, 
 b5mu=-20, b5tau=0.00001, 






 b0mu=0, b0tau=10, 
 b1mu=0, b1tau=10, 
 b2mu=0, b2tau=10, 
 b3mu=0, b3tau=10, 
 b4mu=0, b4tau=10, 
 b5mu=0, b5tau=10, 
 b6mu=0, b6tau=10, 
 tau=10 
 ) 
#model data (head & tail of dataset) 
sex[] age[] bo[] lo[] death[] t[] Y[] 
0 46 1 0 1 250 33 
1 77 0 1 0 154 4 
0 63 0 1 0 401 6 
0 41 0 1 1 89 8 
.... 
1 66 0 1 1 119 9 
0 48 1 1 1 434 26 
0 55 0 1 0 184 2 































predict(scorechg.lm, new, interval="confidence",level=.975) 
liz<-data.frame(time=730,sex=0,age=55,bo=0,lo=1,death=1) 





jagdata<-list(sex=sex, age=age, bo=bo, lo=lo, 




for (i in 1:1000) { 
 Y[i] ~ dnorm(mu[i], tau) 
 x2[i] <- equals(sex[i],1) 
 x4[i] <- equals(bo[i],1) 
 x5[i] <- equals(lo[i],1) 
 x6[i] <- equals(death[i],1) 
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 mu[i] <- b0 + b1*time[i] + b2*x2[i] + b3*age[i] + b4*x4[i] + b5*x5[i] + 
b6*x6[i] 
  } 
b0 ~ dnorm(b0mu, b0tau) 
 b1 ~ dnorm(b1mu, b1tau) 
 b2 ~ dnorm(b2mu, b2tau) 
 b3 ~ dnorm(b3mu, b3tau) 
 b4 ~ dnorm(b4mu, b4tau) 
 b5 ~ dnorm(b5mu, b5tau)   
 b6 ~ dnorm(b6mu, b6tau) 
b0mu ~ dnorm(0, 10000) 
  b1mu ~ dnorm(0, 10000) 
  b2mu ~ dnorm(0, 10000) 
  b3mu ~ dnorm(0, 10000) 
  b4mu ~ dnorm(0, 10000) 
  b5mu ~ dnorm(0, 10000) 
  b6mu ~ dnorm(0, 10000) 
b0tau ~ dgamma(0.001, 0.001) 
   b1tau ~ dgamma(0.001, 0.001) 
   b2tau ~ dgamma(0.001, 0.001) 
   b3tau ~ dgamma(0.001, 0.001) 
   b4tau ~ dgamma(0.001, 0.001) 
   b5tau ~ dgamma(0.001, 0.001) 
   b6tau ~ dgamma(0.001, 0.001) 
tau ~ dgamma(0.001, 0.001) 
 sig2 <- 1/sqrt(tau) 
   b0sig2 <- 1/sqrt(b0tau) 
   b1sig2 <- 1/sqrt(b1tau) 
   b2sig2 <- 1/sqrt(b2tau) 
   b3sig2 <- 1/sqrt(b3tau) 
   b4sig2 <- 1/sqrt(b4tau) 
   b5sig2 <- 1/sqrt(b5tau) 
   b6sig2 <- 1/sqrt(b6tau) 






 "b0mu"=3, "b0tau"=0.001, 
 "b1mu"=0.019, "b1tau"=0.001, 
 "b2mu"=-0.264, "b2tau"=0.001, 
 "b3mu"=-0.024, "b3tau"=0.001, 
 "b4mu"=1.256, "b4tau"=0.001, 
 "b5mu"=-0.803, "b5tau"=0.001, 







   "b3mu","b3sig2","b3", "b4mu","b4sig2","b4",  
   "b5mu","b5sig2","b5", "b6mu","b6sig2","b6",  
   "sig2", "mu") 
 
#parameters1<-c("b0", "b1", "b2", "b3", "b4", "b5", "b6", 
#   "sig2") 
jagmodel1<-jags(data = jagdata, inits = jaginits1,  
  parameters.to.save = parameters1, 
  model.file = "jagmod", n.chains = 1,  









 "b0mu"=60, "b0tau"=0.00001, 
 "b1mu"=20, "b1tau"=0.00001, 
 "b2mu"=-20, "b2tau"=0.00001, 
 "b3mu"=-20, "b3tau"=0.00001, 
 "b4mu"=30, "b4tau"=0.00001, 
 "b5mu"=-20, "b5tau"=0.00001, 





   "b3mu","b3sig2","b3", "b4mu","b4sig2","b4",  
   "b5mu","b5sig2","b5", "b6mu","b6sig2","b6",  
   "sig2", "mu") 
#parameters2<-c("b0", "b1", "b2", "b3", "b4", "b5", "b6", 
#   "sig2") 
jagmodel2<-jags(data = jagdata, inits = jaginits2,  
  parameters.to.save = parameters2, 
  model.file = "jagmod", n.chains = 1,  











 "b0mu"=0, "b0tau"=10, 
 "b1mu"=0, "b1tau"=10, 
 "b2mu"=0, "b2tau"=10, 
 "b3mu"=0, "b3tau"=10, 
 "b4mu"=0, "b4tau"=10, 
 "b5mu"=0, "b5tau"=10, 





   "b3mu","b3sig2","b3", "b4mu","b4sig2","b4",  
   "b5mu","b5sig2","b5", "b6mu","b6sig2","b6",  
   "sig2", "mu") 
#parameters3<-c("b0", "b1", "b2", "b3", "b4", "b5", "b6", 
#   "sig2") 
jagmodel3<-jags(data = jagdata, inits = jaginits3,  
  parameters.to.save = parameters3, 
  model.file = "jagmod", n.chains = 1,  






































legend('topright', c('reg', 'reg1', 'reg2', 'reg3'), 
  lty=c(1,4,6,8),  
  col=c('black','green','blue','red'), 




plot(time,Y,pch=20,col="gray", xlim=c(100,300), ylim=c(0,15)) 
abline(regplot,col="black",lwd=3) 
points(time[1:N], mujags1, col="green", pch=22) 
abline(reg1, col="green",lwd=4) 
points(time[1:N], mujags2, col="blue", pch=4) 
abline(reg2, col="blue",lwd=3,lty="dashed") 





plot(time,Y,pch=20,col="gray", xlim=c(400,600), ylim=c(10,25)) 
abline(regplot,col="black",lwd=3) 
points(time[1:N], mujags1, col="green", pch=22) 
abline(reg1, col="green",lwd=4) 
points(time[1:N], mujags2, col="blue", pch=4) 
abline(reg2, col="blue",lwd=3,lty="dashed") 










Inference for Bugs model at "jagmod", fit using jags, 
 1 chains, each with 5000 iterations (first 500 discarded) 
 n.sims = 4500 iterations saved 
          mu.vect sd.vect     2.5%      25%      50%      75%    97.5% 
b0          2.562   2.311   -0.312    0.313    2.271    4.230    7.527 
b1          0.021   0.002    0.016    0.019    0.021    0.022    0.025 
b2         -0.058   0.342   -0.896   -0.168   -0.016    0.081    0.626 
b3         -0.012   0.030   -0.074   -0.032   -0.010    0.010    0.037 
b4          0.884   1.003   -0.530    0.040    0.677    1.620    2.967 
b5         -0.692   1.008   -2.942   -1.361   -0.337    0.004    0.803 
b6          7.315   0.697    5.940    6.848    7.304    7.781    8.696 
sig2        9.506   0.214    9.114    9.358    9.499    9.649    9.929 
 
jagmodel2 
Inference for Bugs model at "jagmod", fit using jags, 
 1 chains, each with 5000 iterations (first 500 discarded) 
 n.sims = 4500 iterations saved 
          mu.vect sd.vect     2.5%      25%      50%      75%    97.5% 
b0          2.545   2.347   -0.353    0.283    2.246    4.205    7.413 
b1          0.021   0.002    0.016    0.019    0.021    0.022    0.025 
b2         -0.049   0.338   -0.851   -0.168   -0.019    0.086    0.642 
b3         -0.012   0.030   -0.074   -0.032   -0.009    0.010    0.038 
b4          0.879   0.987   -0.597    0.042    0.717    1.613    2.896 
b5         -0.684   1.000   -2.969   -1.354   -0.323    0.007    0.755 
b6          7.327   0.711    5.932    6.847    7.315    7.811    8.713 
sig2        9.506   0.213    9.100    9.360    9.501    9.647    9.934 
 
jagmodel3 
Inference for Bugs model at "jagmod", fit using jags, 
 1 chains, each with 5000 iterations (first 500 discarded) 
 n.sims = 4500 iterations saved 
          mu.vect sd.vect     2.5%      25%      50%      75%    97.5% 
b0          2.455   2.343   -0.410    0.235    2.058    4.122    7.490 
b1          0.021   0.002    0.016    0.019    0.021    0.022    0.025 
b2         -0.052   0.334   -0.866   -0.163   -0.017    0.082    0.631 
b3         -0.012   0.030   -0.077   -0.032   -0.009    0.011    0.038 
b4          0.933   0.982   -0.452    0.055    0.810    1.686    2.943 
b5         -0.643   0.984   -2.881   -1.273   -0.251    0.015    0.715 
b6          7.340   0.696    5.991    6.869    7.342    7.802    8.753 
sig2        9.505   0.212    9.106    9.358    9.505    9.646    9.934 
 
 
